🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 3 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
12/06/2019 7,91 8,53 7,82 8,29 +6,42% 8,95% 239.500
11/06/2019 8,06 8,12 7,49 7,79 -2,75% 7,88% 216.200
10/06/2019 8,06 8,29 7,96 8,01 -0,62% 4,09% 199.300
07/06/2019 8,00 8,30 7,83 8,06 +0,88% 5,88% 192.000
06/06/2019 7,99 8,01 7,81 7,99 -0,25% 2,50% 101.900
05/06/2019 8,07 8,09 7,73 8,01 -0,12% 4,46% 207.400
04/06/2019 7,77 8,19 7,40 8,02 +4,02% 10,17% 283.300
03/06/2019 8,48 8,50 7,60 7,71 -9,08% 10,61% 242.300
31/05/2019 8,64 8,74 8,35 8,48 -2,97% 4,51% 101.700
30/05/2019 8,75 8,85 8,56 8,74 +0,34% 3,31% 69.500
29/05/2019 8,80 8,80 8,50 8,71 -2,13% 3,41% 73.800
28/05/2019 8,96 9,13 8,85 8,90 -0,67% 3,13% 118.500
24/05/2019 9,22 9,49 8,90 8,96 -0,88% 6,40% 117.200
23/05/2019 9,39 9,58 8,98 9,04 -5,04% 6,39% 128.800
22/05/2019 9,65 9,70 9,17 9,52 -1,75% 5,49% 37.300
21/05/2019 9,66 9,91 9,43 9,69 +0,52% 5,01% 81.000
20/05/2019 9,35 10,00 9,32 9,64 +1,90% 7,27% 91.900
17/05/2019 9,84 9,87 8,99 9,46 -4,73% 8,94% 168.600
16/05/2019 9,79 10,18 9,70 9,93 +2,06% 4,90% 117.100
15/05/2019 9,82 10,20 9,64 9,73 -2,41% 5,70% 134.800
14/05/2019 10,13 10,20 9,70 9,97 -1,09% 4,99% 87.300
13/05/2019 10,64 10,76 10,01 10,08 -7,10% 7,05% 88.200
10/05/2019 10,96 11,14 10,68 10,85 -1,36% 4,20% 64.800
09/05/2019 11,02 11,29 10,78 11,00 -0,18% 4,58% 76.500
08/05/2019 11,00 11,31 10,87 11,02 +0,64% 4,05% 139.900
07/05/2019 10,39 11,09 10,35 10,95 +3,99% 7,12% 215.600
06/05/2019 10,29 10,70 10,07 10,53 +0,00% 6,12% 46.100
03/05/2019 10,08 10,83 9,79 10,53 +5,72% 10,32% 132.800
02/05/2019 9,94 10,15 9,21 9,96 -0,80% 9,46% 151.900
01/05/2019 9,75 10,33 9,30 10,04 +3,29% 10,56% 147.500